{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"34"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"75"}],"title":"SD"},{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"}],"title":"PD"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"title":"Non-CR/Non-PD"},{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"}],"title":"NE"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 participants only","reportingStatus":"POSTED","timeFrame":"Up to 32 months","title":"Part 2: BOR Per IRC","type":"SECONDARY","unitOfMeasure":"Participants"}